Related references
Note: Only part of the references are listed.Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice
Maria Buur Nordskov Gabe et al.
BRITISH JOURNAL OF PHARMACOLOGY (2023)
Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology
Sarina Gadgaard et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment
Maria Buur Nordskov Gabe et al.
PHARMACOLOGICAL RESEARCH (2022)
N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 receptor selectivity towards more GLP-1 receptor interaction
Maria Buur Nordskov Gabe et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure
Marco Pizzoferrato et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2022)
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda et al.
MOLECULES (2022)
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism-A Randomized Crossover Study
Kirsa Skov-Jeppesen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor
Florent X. Smit et al.
STRUCTURE (2021)
GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats
Wijnand J. C. van der Velden et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system
Maria Buur Nordskov Gabe et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2020)
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome
Diane M. Hargrove et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens Juul Holst et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Matthew P. Gilbert et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor
Wen Sun et al.
CELL RESEARCH (2020)
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Animal to human translation: a systematic scoping review of reported concordance rates
Cathalijn H. C. Leenaars et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats
Bing'er Xu et al.
LIFE SCIENCES (2019)
GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men
Kirsa Skov-Jeppesen et al.
BONE (2019)
Localization of Glucagon-Like Peptide-2 Receptor Expression in the Mouse
Bernardo Yusta et al.
ENDOCRINOLOGY (2019)
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors
Maria Buur Nordskov Gabe et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Endogenous glucagon-like peptide-1 and 2 are essential for regeneration after acute intestinal injury in mice
Rasmus Hytting-Andreasen et al.
PLOS ONE (2018)
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Ben Jones et al.
NATURE COMMUNICATIONS (2018)
Cryo-EM structure of the active, G(s)- protein complexed, human CGRP receptor
Yi-Lynn Liang et al.
NATURE (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Insulin Secretion Depends on Intra- islet Glucagon Signaling
Berit Svendsen et al.
CELL REPORTS (2018)
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Yan Zhang et al.
NATURE (2017)
GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release
A. H. Sparre-Ulrich et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
A. H. Sparre-Ulrich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor
L. S. Hansen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance
Kazimierz Wisniewski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine
Jens Pedersen et al.
PEPTIDES (2015)
Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration
Noura El-Jamal et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2014)
Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2
Daniel J. Drucker et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 76 (2014)
A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk
S. S. Torekov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis
Ke-ke Qi et al.
PEPTIDES (2014)
Acylation of Glucagon-Like Peptide-2: Interaction with Lipid Membranes and In Vitro Intestinal Permeability
Sofie Trier et al.
PLOS ONE (2014)
A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists
Kazuto Yamazaki et al.
BIOMEDICAL RESEARCH-TOKYO (2013)
Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides
Lei Diao et al.
CLINICAL PHARMACOKINETICS (2013)
Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure
Carsten Askov-Hansen et al.
REGULATORY PEPTIDES (2013)
GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn's Disease Model
Susan E. Alters et al.
PLOS ONE (2012)
Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domain
Kalyana C. Venneti et al.
FEBS LETTERS (2011)
Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
Dennis B. Henriksen et al.
BONE (2009)
Glucagon-like peptide-2 increases mesenteric blood flow in humans
Lasse Bremholm et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects
Jean-Francois Marier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract
Ida B. Gottschalck et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome
Ida B. Gottschalck et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas
J. de Heer et al.
DIABETOLOGIA (2007)
Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs
Rasmus Jorgensen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Disassociation of bone resorption and formation by GLP-2 - A 14-day study in healthy postmenopausal women
Dennis B. Henriksen et al.
BONE (2007)
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans
JJ Meier et al.
GASTROENTEROLOGY (2006)
GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors
C Orskov et al.
REGULATORY PEPTIDES (2005)
Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1
R Ugleholdt et al.
ENDOCRINOLOGY (2004)
Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
DB Henriksen et al.
BONE (2004)
Role of gastrointestinal hormones in postprandial reduction of bone resorption
DB Henriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
GLP-1 derivative liraglutide in rats with β-cell deficiencies:: influence of metabolic state on β-cell mass dynamics
J Sturis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
The G-protein-coupled receptors in the human genome form five main families.: Phylogenetic analysis, paralogon groups, and fingerprints
R Fredriksson et al.
MOLECULAR PHARMACOLOGY (2003)
Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon
KV Haderslev et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2002)
The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist
J Thulesen et al.
REGULATORY PEPTIDES (2002)
Modulation of specific intestinal epithelial progenitors by enteric neurons
M Bjerknes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
PB Jeppesen et al.
GASTROENTEROLOGY (2001)
Structural determinants for activity of glucagon-like peptide-2
MP DaCambra et al.
BIOCHEMISTRY (2000)
Enteroendocrine localization of GLP-2 receptor expression in humans and rodents
B Yusta et al.
GASTROENTEROLOGY (2000)
Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats
W Tavares et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2000)
Share Paper
